v3.23.3
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Research and development expenses $ 469 $ 468 $ 1,570 $ 1,357
Marketing expenses 297 24 631 205
General and administrative expenses 431 384 1,448 1,138
Total operating loss 1,197 876 3,649 2,700
Financial income, net (18) (20) (11) (56)
Loss for the period $ 1,179 $ 856 $ 3,638 $ 2,644
Basic loss per common stock $ (0.02) $ (0.01) $ (0.05) $ (0.04)
Dilutive loss per common stock $ (0.02) $ (0.01) $ (0.05) $ (0.04)
Weighted average number of ordinary shares basic 68,836,598 68,720,970 69,233,573 67,186,877
Weighted average number of ordinary shares diluted 68,836,598 68,720,970 69,233,573 67,186,877

Source